Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/186947
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Latest advances in the development of eukaryotic vaults as targeted drug delivery systems |
Autor: | Muñoz-Juan, Amanda; Carreño, Aida; Mendoza, Rosa; Corchero, José Luis | Palabras clave: | Eukaryotic vaults Nanoparticles Drug delivery systems Nanocage Protein self-assembly |
Fecha de publicación: | 28-jun-2019 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Pharmaceutics 11(7): 300 (2019) | Resumen: | The use of smart drug delivery systems (DDSs) is one of the most promising approaches to overcome some of the drawbacks of drug-based therapies, such as improper biodistribution and lack of specific targeting. Some of the most attractive candidates as DDSs are naturally occurring, self-assembling protein nanoparticles, such as viruses, virus-like particles, ferritin cages, bacterial microcompartments, or eukaryotic vaults. Vaults are large ribonucleoprotein nanoparticles present in almost all eukaryotic cells. Expression in different cell factories of recombinant versions of the “major vault protein” (MVP) results in the production of recombinant vaults indistinguishable from native counterparts. Such recombinant vaults can encapsulate virtually any cargo protein, and they can be specifically targeted by engineering the C-terminus of MVP monomer. These properties, together with nanometric size, a lumen large enough to accommodate cargo molecules, biodegradability, biocompatibility and no immunogenicity, has raised the interest in vaults as smart DDSs. In this work we provide an overview of eukaryotic vaults as a new, self-assembling protein-based DDS, focusing in the latest advances in the production and purification of this platform, its application in nanomedicine, and the current preclinical and clinical assays going on based on this nanovehicle. | Descripción: | © 2019 by the authors. | Versión del editor: | https://doi.org/10.3390/pharmaceutics11070300 | URI: | http://hdl.handle.net/10261/186947 | DOI: | 10.3390/pharmaceutics11070300 | ISSN: | 1999-4923 | E-ISSN: | 1999-4923 |
Aparece en las colecciones: | (ICMAB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Latest_Muñoz_Art2019.pdf | 2,14 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
12
checked on 29-abr-2024
SCOPUSTM
Citations
19
checked on 02-may-2024
WEB OF SCIENCETM
Citations
18
checked on 23-feb-2024
Page view(s)
193
checked on 07-may-2024
Download(s)
141
checked on 07-may-2024